Therefore, lipid based formulation can be employed for lymphatic voyage of anti-cancer drugs with additional benefits of P-gp and CYP3A4 modulation for drugs having poor hydrophilicity, low intestinal permeation and high CYP3A4 mediated metabolic activity. The gene discussed is CYP3A4; the disease is cancer.